Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0620920230550020443
Experimental & Molecular Medicine
2023 Volume.55 No. 2 p.443 ~ p.456
Fibulin2: a negative regulator of BMSC osteogenic differentiation in infected bone fracture healing
Shi-Dan Li

Wei Xing
Shao-Chuan Wang
You-Bin Li
Hao Jiang
Han-Xuan Zheng
Xiao-Ming Li
Jing Yang
De-Bin Guo
Xiao-Yu Xie
Ren-Qing Jiang
Chao Fan
Lei Li
Xiang Xu
Jun Fei
Abstract
Bone fracture remains a common occurrence, with a population-weighted incidence of approximately 3.21 per 1000. In addition, approximately 2% to 50% of patients with skeletal fractures will develop an infection, one of the causes of disordered bone healing. Dysfunction of bone marrow mesenchymal stem cells (BMSCs) plays a key role in disordered bone repair. However, the specific mechanisms underlying BMSC dysfunction caused by bone infection are largely unknown. In this study, we discovered that Fibulin2 expression was upregulated in infected bone tissues and that BMSCs were the source of infection-induced Fibulin2. Importantly, Fibulin2 knockout accelerated mineralized bone formation during skeletal development and inhibited inflammatory bone resorption. We demonstrated that Fibulin2 suppressed BMSC osteogenic differentiation by binding to Notch2 and inactivating the Notch2 signaling pathway. Moreover, Fibulin2 knockdown restored Notch2 pathway activation and promoted BMSC osteogenesis; these outcomes were abolished by DAPT, a Notch inhibitor. Furthermore, transplanted Fibulin2 knockdown BMSCs displayed better bone repair potential in vivo. Altogether, Fibulin2 is a negative regulator of BMSC osteogenic differentiation that inhibits osteogenesis by inactivating the Notch2 signaling pathway in infected bone.
KEYWORD
Mechanisms of disease, Mesenchymal stem cells
FullTexts / Linksout information
Listed journal information